INTRODUCTION

Generalized pustular psoriasis (GPP) is a chronic, non-communica-
ble inflammatory skin disease which can involve multiple organs and
potentially lead to a fatal outcome. GPP is characterized by acute,
recurrent flares of sterile pustular lesions on erythematous skin
with signs of systemic inflammation also affecting extracutaneous
organs. It can be associated with a pre-existing plaque psoriasis or
develop independently. Due to its low prevalence, it is defined as an
orphan disease.1-3

In our review article of 2018 “Generalized pustular psoriasis—a
model disease for specific targeted immunotherapy,” we presented
the concept that GPP is an ideal disease to illustrate current prob-
lems in the field of inflammatory skin diseases—starting from a
precise definition of this heterogeneous disease overlapping with
other types of pustular diseases,4 advances in understanding the

Abstract

Generalized pustular psoriasis (GPP) is a rare, inflammatory skin disease characterized by recurrent flares of pustulation accompanied by systemic symptoms. Due to its acuteness, sufficient diagnosis and treatment are essential, but often face challenges. We recently overviewed various treatment options of GPP utilizing established therapies in psoriasis vulgaris (PsO). Although there is a pathogenic relation to PsO, more and more evidence suggests a predominant involvement of the innate immune system in GPP. Recent discoveries on the genetic background of GPP with underlying mutations in IL36RN, CARD14, AP1S3 and SERPINA3 contributed to a better understanding of the pathogenesis and provide major opportunities in the development of innovative, targeted therapies. The proposed umbrella term "auto-inflammatory keratinization diseases" (AIKD) helps to categorize this heterogeneous disease. Finally, we address the problem of insufficient standardized assessment tools and propose a reproducible scoring system also capturing the systemic features of GPP. In summary, GPP is a prototype disease to demonstrate both obstacles and progress in dermatology—currently insufficient definition and diagnostic tools on the one hand side, yet major advances in dissecting disease heterogeneity, opportunities for novel diagnostic techniques and therapeutic decision-making based on molecular events on the other side.

KEYWORDS

biologics, generalized pustular psoriasis, inflammatory skin diseases, targeted immunotherapy
pathogenesis of GPP, over standardized diagnostic approaches and ultimately targeted therapies. We concluded that there was no consensus whether GPP is to be regarded a variant of psoriasis vulgaris (PsO) or a distinct clinical entity with overlapping pathological findings to PsO. Moreover, we discussed how the lack of standardized clinical criteria for diagnosis challenged the classification of GPP. We summarized that in accordance with the pathogenetic overlap to PsO, several targeted immunotherapies including anti-TNF α, anti-IL23/12 or anti-IL17 were investigated with good success in GPP.

In this viewpoint essay, we discuss how this approach has continued in the last 2 years—with novel insights into genetics and the pathogenesis of GPP, a proposed classification system, a new diagnostic assessment tool and new as well as ongoing clinical trials. Today, GPP stands exemplary for an autoinflammatory disease with high unmet medical need for disease stratification and identification of biomarkers on the way to personalized medicine.

2 | NEW LABEL FOR GPP—AN AUTOINFLAMMATORY KERATINIZATION DISEASE

In our review of 2018, we discussed the problematic definition of GPP, regarded as a subtype of psoriasis by some authors versus as a distinct clinical entity by others. We summarized that the pathogenesis of GPP partly overlaps with typical pathways of PsO, but exhibits a pronounced activation of the innate immune system. Therefore, cytokines such as IL17A, IL22, IL23, TNF and interferons are found to be elevated in both PsO and GPP. However, GPP lesions showed higher IL-1 and IL-36 expressions compared to PsO lesions.5,6

In 2011, Marrakchi et al laid the foundation on a new autoinflammatory perspective of GPP by discovering an underlying genetic mutation of the IL36 receptor antagonist (IL36RN) in several cases of familiar GPP which led to the term DITRA (deficiency of IL36 receptor antagonist).7 This missense mutation of the IL36RN results in a deficiency of IL36 receptor antagonist, an anti-inflammatory cytokine of the IL1-family, which normally antagonizes the binding of IL-36 cytokines (IL-36α, IL-36β and IL-36γ), mainly derived from keratinocytes, to the receptor and therefore inhibits downstream inflammatory pathways via NF-κB. The dis-inhibition leads to an uncontrolled binding of IL-36 to the IL36 receptor resulting in enhanced signal transduction of pro-inflammatory cytokines, for example IL-8, which is essential for the migration of neutrophils (Figure 1).5,7,8 Data on the prevalence of DITRA in GPP patients vary significantly ranging from 23.7% to 82%, showing an association to GPP without concomitant PsO and therefore proposing a different genetic background of GPP without PsO than GPP with PsO.5,11 In their review of 2018, Furue et al highlighted the role of IL-36 signalling in plaque psoriasis and pustular

**FIGURE 1** Pathogenesis and genetics of GPP (main mediators) including targets for immunotherapy. For a detailed explanation of GPP pathogenesis, we refer to our previous review of 2018.4,3
psoriasis and concluded that IL-36 is predominantly involved in the pathogenesis of pustular psoriasis, while the TNF-α/IL-23/IL-17/IL-22 axis mainly drives plaques psoriasis. However, both pathways are highly related and influence each other via a positive inflammatory loop.12

These findings consecutively led to a proposed classification of GPP as an autoinflammatory disease. Autoinflammation per se is characterized by sterile inflammation without pathogenic autoantibodies or auto-reactive T lymphocytes and by dysregulation of the inflamasome, a cytosolic multi-protein complex in innate immune cells. This leads to an excessive maturation and secretion of IL-1β and IL-18.9 Patients typically present with recurrent or persistent systemic inflammation (eg fever), abdominal and chest pain and skin symptoms.8 Classical autoinflammatory diseases present with skin symptoms such as urticarial eruptions, erythema nodosum-like lesions, pustules, pyoderma gangrenosum or erysipelas-like erythema. Typical representatives include familial Mediterranean fever (FMF), cryopyrin-associated periodic syndrome (CAPS), TNF receptor-associated periodic fever syndrome (TRAPS) and syndrome of pyogenic arthritis with pyoderma gangrenosum and acne (PAPA). However, hyperkeratotic skin lesions are uncommon in autoinflammatory diseases.13

More recently, a subtype of pityriasis rubra pilaris (PRP), a papulosquamous skin disease, was included to the category of autoinflammatory diseases due to the identification of three different homozygous mutations in CARD14, a known activator of the pro-inflammatory nuclear factor kappa B (NF-xB).9,14 Previously, similar mutations were identified in a subset of familial psoriasis.14,15 The first description of a CARD14 mutation in a child with sporadic, early-onset generalized pustular psoriasis was followed by identifying a significant association between CARD14 and GPP with concomitant PsO in a small Japanese cohort in 2014.15,16

Today, we know that a gain-of-function mutation in caspase recruitment domain family 14 (CARD14), an underlying mutation in IL-36RN, CARD14 or AP1S3, Pityriasis rubra pilaris type V (CARD 14) and familial keratitis lichenoides chronica (NLRP1).6,20 Currently, most AIKD entities are difficult to treat and severely affect quality of life. Through a better understanding of the pathophysiology of AIKD in the future, new and innovative targeted therapies might be discovered.13

3 | ASSESSING THE SEVERITY OF GPP IS STILL CHALLENGING

The diagnosis and management of GPP are still challenging, especially due to its episodic nature and systemic component. For the development of sufficient therapeutic strategies and the assessment of treatment response, standardized scoring systems are essential. So far, there are no validated scoring systems available. Assessment tools for GPP in clinical trials vary and are frequently adapted from those for adult PsO adding pustular criteria to established scoring systems. The generalized pustular psoriasis area and severity index (GPPASI), for instance, is an adaption of PASI for PsO, in which the induration component is exchanged with a pustular component and therefore consists of erythema, scaling and pustules combined with the percentage of body surface area affected. It provides a numeric scoring ranging from 0 to 72 (maximum).21

Another commonly used assessment tool for GPP is the generalized pustular psoriasis physician global assessment (GPPGA), adapted from the PGA used in psoriasis.22 For GPPGA, all lesions are scored from 0-4 (clear-severe) regarding erythema, pustules and scaling. The final score is calculated by taking the average of the separately graded criteria.21

To address the problem of solely skin-based scoring systems in GPP that neglect the assessment of systemic symptoms in a systemic disease, a new PsO independent scoring tool was developed in 2014. The Japanese Dermatological Association (JDA) severity index of GPP was introduced in the GPP Medical Practice Guideline (GPPGA). A new PsO independent scoring tool was developed in 2014. The Japanese Dermatological Association (JDA) severity index of GPP was introduced in the GPP Medical Practice Guideline (GPPGA).
area. The scoring ranges from 3 to 0 (severe, moderate, mild, none) with a maximum of 9 points. Secondly, the systemic involvement is assessed via pyrexia, white blood cell count, CRP and serum albumin with scores ranging from 2 to 0 (maximum 8 points). The sum of those two categories represents the total JDA severity index score of GPP varying from severe (17-11 points), moderate (10-7 points) to mild (0-6 points).23 (Table 1).

Stephenson et al. allude to this topic on reporting on a 4-year-old Caucasian boy with an underlying mutation in IL36RN, who developed pustular lesions with systemic symptoms at the age of 2. They suggest to assess the severe extracutaneous manifestations of this autoinflammatory DITRA disease via the autoinflammatory disease activity index (AIDAI) due to its symptom overlap to other autoinflammatory diseases.24

AIDAI was originally developed for other inherited autoinflammatory diseases such as familial Mediterranean fever (FMF) and consists of 12 items (fever, overall symptoms, abdominal pain, nausea/vomiting, diarrhea, chest pain, painful nodes, arthralgia or myalgia, swelling of the joints, eye manifestations and skin rash) which are scored every day with 0 (no symptoms present) or 1 (symptoms present). A monthly score ≥9 out of 372 maximum points is described as an "active disease." For the scoring of skin focussed autoinflammatory diseases, the authors propose the 15-item DITRA/Autoinflammatory Keratinization Diseases Activity Index (DITRA/AIKD-AI), which consists of AIDAI and additionally particularizes "skin rash" into pustular, plaque-type with keratinization or unspecified and adds geographic tongue as a single criterion.24 With further future validation, this specified assessment tool could be used not only to monitor disease activity but also provide a way to measure treatment response in multiple organs.

In our opinion, DITRA/AIKD-AI presents a detailed and comprehensive assessment of symptoms in GPP which might be used within clinical trials, but lacks feasibility in daily practice due to its time-consuming documentation. Adapted scores from PsO lack the evaluation of systemic symptoms in GPP. Therefore, we favour the practicable JDA severity index to be used as a standardized assessment tool in GPP in both clinical routine and clinical trials.

4 | NOVEL THERAPEUTIC OPTIONS IN GPP

We previously summarized the various treatment options for GPP, emphasizing the role of specific targeted immunotherapies in GPP. Due to its pathological overlap, we presented well-established biologics from PsO as promising treatment options in GPP. There are published data of successful management of GPP with therapeutic antibodies directed against TNF-α (infliximab, etanercept, adalimumab), IL-12/-23 (ustekinumab) and IL-17 (secukinumab, ixekizumab, brodalumab).23,25-36 Unlike PsO, there is no GPP-specific medication approved in Europe and the United States until today, although there is an urgent need for treatment in this potentially life-threatening disease.27
| Target          | Drug             | Dose               | Efficacy         |
|-----------------|------------------|--------------------|------------------|
|                 |                  |                    | Pustule, clearance, d | Clinical improvement |
| TNF-α (n = 55)  | Infliximab (n = 29) | NA                 | 2                | 8/10            |
|                 |                  | Like PV            | 1                | 3/3             |
|                 |                  | Like PV            | 2                | 4/4             |
|                 |                  | Like PV            | 3                | 3/3             |
|                 |                  | Like PV            | 2                | 1/1             |
|                 |                  | Like PV            | 1                | 1/1             |
|                 |                  | Like PV            | 2                | 1/1             |
|                 |                  | Like PV            | 4-5 mg/kg bw     | 3               | 2/2             |
|                 |                  |                    | 3 mg/kg bw       | 2               | 2/2             |
| Adalimumab (n = 15) | NA             | 17.5               | 2                 | 2/3             |
|                 |                  | 80 mg eow          | 4                 | 4/4             |
|                 |                  | Like PV            | 2                 | 1/1             |
|                 |                  | Like PV            | 2                 | 1/1             |
|                 |                  | 80 mg eow          | 5                 | 1/1             |
|                 |                  | Like PV            | 40 mg ew          | 5               | 1/1             |
|                 |                  | Like PV            | 5                 | 1/1             |
| Etanercept (n = 11) | NA             | 18                 | 2                 | 2/4             |
|                 |                  | 25-50 mg BIW       | 6                 | 6/6             |
|                 |                  | 50 mg BIW          | 0                 | 0/1             |
| IL-12/IL-23 (p40) (n = 7) | Ustekinumab (n = 7) | Like PV          | NA               | 4/4             |
|                 |                  | Like PV            | NA               | 0/1             |
|                 |                  | Like PV            | NA               | 1/1             |
|                 |                  | Like PV            | NA               | 1/1             |
| IL-23 (p19) (n = 8) | Guselkumab (n = 8) | 50 mg week 0.4, e8w, dose escalation | NA | 7/8 |
|                 |                  | 100 mg/d           | 1                 | 1/1             |
| IL-1 (n = 7)    | Anakinra (n = 4) | 100 mg/d           | NA               | 1/1             |
|                 |                  | 100 mg/d           | NA               | 1/1             |
|                 |                  | NA                 | 2                 | 2/2             |
| IL-17 (n = 32)  | Broda-lumab (n = 12) | 140-210 mg eow | NA               | 9/12            |
|                 | Ixekizumab (n = 5) | Like PV            | NA               | 5/5             |
|                 | Sekukinumab (n = 15) | Like PA-PV        | NA               | 10/12           |
|                 |                  | Like PV            | 2                 | 1/1             |
|                 |                  | Like PV            | NA               | 1/1             |
| IL-36 (n = 7)   | Spesolimab (n = 7) | 10 mg/kg bw iv single dose | NA | 7/7 |

Abbreviations: BIW, biweekly; bw, body weight; CaR, case report; CaS, case series; CR, complete response; CT, clinical trial; CTP3, clinical trial phase 3; CyA, cyclosporin A; d, day; DITRA, deficiency of the IL-36 receptor [IL-36R] antagonist; eow, every other week; e4w, every four weeks; IL, interleukin; MTX, methotrexate; NA, not available; NR, no or weak response; OL, open label; PA, psoriasis arthritis; PR, partial response; PV, psoriasis vulgaris; TNF, tumor necrosis factor.

aAnalysis at week 16, one patient discontinued the study.
bAnalysis at week 16, one patient discontinued study due to AEBIW.
| Type of clinical response | Concomitant immunosuppressant medication | Type of DITRA; Type of CARD14 | Type | Author |
|---------------------------|-----------------------------------------|-------------------------------|------|--------|
| CR (NA), PR(NA), NR (2)  | Acitretin 35 mg/d                       | 12/10 (2); 2NA               | CA5  | Viguier |
| CR (2), PR (1)           |                                         | CA5                           | Poulalhon |
| PR(2), CR (2)            |                                         | CA5                           | Matsumoto |
| CR (3)                   |                                         | 12/3 (2); 2NA                 | CA5  | Sugiuira |
| PR                       |                                         | CA5                           | Chandran |
| PR                       |                                         | CA5                           | Smith |
| PR                       |                                         | CA5                           | Newland |
| CR                       |                                         | CA5                           | Schmick |
| CR                       | Acitretin 20 mg/d                       | 11/3 (1); 2NA                 | CA5  | Viguier |
| CR (2)                   | Prednisolon 30 mg/d (1)                 | NA                            | CA5  | Matsumoto |
| CR (1), CR(1)            | Acitretin 20 mg/d                       | NA                            | CA5  | Kim |
| PR(2), CR (2)            | CyA 400 mg/d and MTX 20 mg/w            | NA                            | CA5  | Gallo |
| CR                       | Acitretin 50 mg/d                       | NA                            | CA5  | Kawakami |
| PR(2)                    | MTX 5 mg/d                             | NA                            | CA5  | Kim |
| PR                       |                                         | 11/1 (1); 2NA                 | CA5  | Zangrilli |
| CR                       |                                         | NA                            | CA5  | Gkalpakiotis |
| CR (NA), PR(NA), NR (2)  | MTX 10 mg/d                            | 12/4 (1); 2NA                 | CA5  | Viguier |
| CR (6)                   | CyA                                     | 11/4; 2NA                     | CA5  | Matsumoto |
| NR                       |                                         | 11/1; 2NA                     | CA5  | Storan |
| CR (4)                   | Acitretin 10-20 mg/d (3)                | 11/4; 2NA                     | CA5  | Dauden |
| NR                       | CyA                                     | NA                            | CA5  | Shigetoshi |
| CR                       |                                         | NA                            | CTP3 OL | |
| CR (4), PR (3), NR (1)   |                                         | NA                            | CTP3 OL | |
| PR                       | Prednisolon                             | 11/1 (1); 2NA                 | CA5  | Huffmeier |
| PR                       | Prednisolon 10 mg/d                     | 11/1 (1); 2NA                 | CA5  | Skendros |
| CR (NA), PR(NA), NR      |                                         | 11/2 (1); 2NA                 | CA5  | Viguier |
| CR                       | Hydroxyurea, Prednisolon                | 11/0; 1; 2NA                  | CA5  | Skendros |
| PR (2)                   |                                         | CT (OL)                       | CA5  | Mansouri |
| CR (6), PR(3), NR(2)b    | Retinoid (1)                            | NA                            | CTP3 OL | Yamasaki |
| CR (2), PR (3)           | Prednisolon < 10 mg/d (NA)              | NA                            | CTP3 OL | Saeki |
| CR(9), PR(1), NR(1)      | CyA (4), Etretinate (3), MTX (1), Prednisolon (1); | NA | CTP3 OL | Imafuku |
| CR                       | MTX                                     | NA                            | CA5  | Böhner |
| CR                       |                                         | NA                            | CA5  | Mugheddu |
| CR                       |                                         | NA                            | CA5  | Polesie |
| CR (7)                   | MTX (1)                                 | 13/7 (3); 21/7 (1)            | CTP1 OL | Bachelez |
In 2017, guselkumab, an IL23-p19 antibody, was approved for the treatment of PsO. One multicentre, open-label, phase-3 study reports on 10 Japanese GPP patients treated with this monoclonal IL-23 antibody at week 0, 4 and then every 8 weeks. Five out of 10 patients showed successful treatment, defined as improvement of the Global Impression Score within the first week, consecutively leading to a 100% success rate in the patients who completed the study (8/10) at week 52, demonstrating efficacy without safety concerns. Currently, there is an ongoing phase-3 trial investigating the efficacy of risankizumab, another anti-IL23-p19 antibody, in GPP patients. Safety was already proven, but publication of efficacy data is still pending.

Since the discovery of the IL36RN mutation in GPP, therapies targeting autoinflammation via inhibition of the inflammasome were followed. Initial studies investigated antibodies targeting IL-1β or the IL-1 receptor (canakinumab, gevokizumab, anakinra) in the treatment of GPP. More recently, a better understanding of the pathogenesis and the genetics of GPP paved the way for the development of specific therapies targeting IL-36.

Published results from a phase-I proof-of-concept study with BI655130 (spesolimab), a monoclonal antibody against the IL-36 receptor, demonstrated a response in all 7 patients after a single intravenous dose. The clinical endpoint (Physician global assessment, PGA 0 or 1 at a five point scale) was achieved in 5 patients during the first week and in all patients by week 4 and maintained over a 20-week period. Interestingly, similar to previous reports on anti-IL-1 treatment in GPP, efficacy was shown regardless of the genetic mutation status, since only 4 patients had an identified homozygous IL36-RN-mutation and 1 patient had a mutation in CARD14 (Table 2). Spesolimab is currently investigated in phase-III clinical trials, without published data so far.

Another humanized monoclonal IL-36-receptor antibody, ANB019, is also currently scrutinized in a clinical trial for GPP.

Table 2 presents an update on the detailed overview of our review from 2018 listing each publication including its specific biologic with dose, efficacy parameters, number of patients, concomitant immunosuppressant medication and the DITRA/CARD14 status.

As discussed in our previous review, there is a potential source of selection bias, since due to the higher prevalence, most of the published cases include Asian patients, exhibiting a different genetic background and therefore results might not apply to other ethnicities. Additionally, in contrast to, for example, Japan, there are no approved biologics for GPP in Europe.

5 THE FUTURE: DISEASE STRATIFICATION BY IDENTIFICATION OF BIOMARKERS?

Advances in our knowledge of genetic variants of GPP, the interaction of autoinflammation and clinical phenotypes, and numerous therapeutic options to treat GPP set the ground for a future of precision medicine in the field. Today, we have opportunities to treat GPP by targeting IL-23, IL-17, TNF-α, IL-1 α/β or IL-36 either blocking the cytokines directly or via their receptors. However, in contrast to PsO, all so far published studies in GPP are one-armed, uncontrolled, open-labelled trials with only a small number of patients and some targets are solely investigated in case reports and case series. Although applying those novel, cost-demanding biologics in GPP comes with good chance to relieve the patient almost completely from disease symptoms, selecting the right treatment for an individual patient remains challenging. Due to the lack of specific objective biomarkers, it is currently impossible to predict the therapeutic response of a given biologic in GPP.

In chronic inflammatory skin diseases, numerous efforts are currently undertaken to identify molecular biomarkers for improving diagnostics, assess disease severity and stratify patients according to chances of therapeutic response. For instance, HLA-C*06:02 genotype has been identified as a biomarker of biologic treatment response in psoriasis predicting the response chances between ustekinumab and adalimumab.

In the era of autoinflammatory keratinization diseases, the CARD14 mutation has recently been proposed as a biomarker predicting therapy response to ustekinumab in familial PRP. Yet, so far biomarkers investigated in GPP like CRP are rather unspecific and solely monitor disease activity. More recently, plasma retinol has been suggested as a predictive biomarker of disease activity and response to acitretin, a conventional treatment option in GPP with rather moderate efficacy. In this study, Yang et al present a significant reduction of plasma retinol levels in GPP patients compared to patients with PsO, which correlated negatively with disease severity. Moreover, response to treatment with acitretin, defined as the reduction of PASI, correlated with an increase of plasma retinol levels.

The oligogenic rather than monogenic inheritance in GPP suggests that even more genetic disorders may underlie the pathogenesis of GPP. This is highlighted by the fact that IL-36 antagonizing biologics succeed even in patients without an identified mutation in relevant genes. Since the genetic background of GPP already indicates differences between GPP with and without concomitant PsO, further studies are needed to explore their role as biomarkers in disease stratification and prediction of therapeutic response. The Pustular Psoriasis Elucidating Underlying Mechanisms (PLUM) study is currently investigating genetic features and associated biomarkers which may complete the understanding of the GPP pathomechanism and lead to an individual-based, personalized targeted medicine in the future.

In summary, more and more genetic and expression biomarkers are proposed to define GPP, assess its severity, or predict therapeutic response. On the other hand, our understanding of the underlying pathogenesis of GPP improves and numerous therapeutic options are available. Once we succeed to implement biomarkers into our therapeutic strategy at an individual patient’s level, GPP can become a driving disease on the way to precision medicine in (auto-) inflammatory skin diseases.
ACKNOWLEDGEMENT
Open access funding enabled and organized by Projekt DEAL.

CONFLICTS OF INTEREST
There are no conflicts of interest.

AUTHOR CONTRIBUTIONS
Dr(s) RN, KE and AB had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. RN and AB conceived and designed the study. RN acquired, analysed and interpreted the data. RN and AB drafted the manuscript. KE and AB critically revised the manuscript for important intellectual content. AB supervised the study. All authors have read and approved the final manuscript.

ORCID
Alexander Boehner https://orcid.org/0000-0003-1590-0805

REFERENCES
[1] B. D. Zelickson, S. A. Muller, Arch Dermatol 1991, 127, 1339.
[2] F. Augey, P. Renaudier, J. F. Nicolas, Eur J Dermatol 2006, 16, 669.
[3] S. E. Choong, N. M. Lai, N. A. Mohammad, N. M. Nanu, K. E. Tey, S. F. Chew, Int J Dermatol 2014, 53, 676.
[4] A. A. Navarini, A. D. Burden, F. Capon, U. Mrowietz, L. Puig, S. Köks, K. Kingo, C. Smith, J. N. Barker, J Eur Acad Dermatol Venereol 2017, 31, 1792.
[5] A. Reis, H. Burkhardt, F. Behrens, M. Köhnm, J. Rech, G. Schett, G. Assmann, K. Kingo, S. Köks, R. Mössner, J. C. Prinz, V. Oji, P. Schulz, L. E. Muñoz, A. E. Kremer, J. Wenzel, U. Höffmeier, J Invest Dermatol 2020, 140, 1451.
[6] K. Sugiura, M. Muto, M. Akiyama, J Invest Dermatol 2014, 134, 1755.
[7] Z. Li, Q. Yang, S. Wang, Medicine 2018, 97, e11741.
[8] N. Setta-Kaffetzi, M. A. Simpson, A. A. Navarini, V. M. Patel, H.-C. Lu, M. H. Allen, M. Duckworth, H. Bachelez, A. D. Burden, S.-E. Choong, CEM Griffiths, B. Kirby, A. Kollos, MMB Seyger, C. Prins, A. Smahi, R. C. Trombath, F. Fraternali, C. H. Smith, J. N. Barker, F. Capon, Am J Hum Genet 2014, 94, 790.
[9] S. Frey, H. Sticht, D. Wilmann-Theis, A. Gerschütz, K. Wolf, S. Löhr, S. Haskamp, B. Frey, M. Hahn, A. B. Ekici, S. Uebe, C. Thiel, K. König, S. Köks, R. Mössner, J. C. Prinz, V. Oji, P. Schulz, L. E. Muñoz, A. E. Kremer, J. Wenzel, U. Höffmeier, J Invest Dermatol 2020, 140, 1451.
[10] A. Khatri, D. Eckert, R. Oberoi, A. Suleiman, Y. Pang, L. Cheng, A. A. Navarini, F. Capon, U. Mrowietz, L. Puig, S. Köks, K. Kingo, C. Smith, J. N. Barker, J Eur Acad Dermatol Venereol 2017, 31, 1792.
[11] R. Mössner, D. Wilsmann-Theis, V. Oji, P. Gkogkolou, S. Löhr, P. Schulz, A. Körber, J. C. Prinz, R. Renner, K. Schäkel, L. Vogelsang, K.-P. Peters, S. Philipp, K. Reich, H. Ständer, A. Jacobi, A. Weyergraf, M. Sticherling, H. Ständer, A. Körber, J. C. Prinz, R. Renner, K. Schäkel, L. Vogelsang, Medizin 2018, 1545, 1.
[12] H. Bachelez, S. E. Choong, S. Mankowski, N Engl J Med 2019, 380, 981.
[13] R. G. Langley, S. R. Feldman, J. Nyirady, P. van de Kerkhof, C. Papavassilis, J Dermatol Treat 2015, 26, 23.
[14] M. Viguier, F. Aubin, E. Delaporte, Arch Dermatol Res 2012, 148, 1423.
[15] C. Stephenson, V. H. Prajapati, C. Hunter, P. Miettunen, Pediatr Dermatol 2020, 37, 670.
[16] S. Twelves, A. Mostafa, N. Dand, E. Burri, K. Farkas, R. Wilson, H. Bachelez, P. Othman, J. Uitto, P. Fleckman, G. Richard, E. Sprecher, Am J Hum Genet 2012, 91, 163.
[17] Z. Z. Yiu, R. B. Warren, Expert Rev Clin Immunol 2019, 15, 507.
[18] M. Viguier, F. Aubin, E. Delaporte, Arch Dermatol Res 2012, 148, 1423.
[19] N. S. Chandran, W. S. Chong, Expert Rev Clin Immunol 2019, 15, 507.
[20] S. Matsuzawa, T. Matsuoka, M. Shimosato, M. Nakamura, M. Kashiwabara, J Dermatolog Treat 2018, 29, 426.
[21] C. E. Griffiths, R. B. Etherley, A. M. Bowcock, R. Goldbach-Mansky, M. A. Lowes, A. M. Bowcock, Am J Hum Genet 2012, 90, 784.
[22] H. Bachelez, S. E. Choong, S. Mankowski, N Engl J Med 2019, 380, 981.
[43] A. Boehner, A. A. Navarini, K. Eyerich, Exp Dermatol 2018, 27, 1067.
[44] K. Eyerich, S. Eyerich, J Eur Acad Dermatol Venereol. 2018, 32, 692.
[45] N. Garzorz-Stark, L. Krause, F. Lauffer, A. Atenhan, J. Thomas, S. P. Stark, R. Franz, S. Weidinger, A. Balato, N. S. Mueller, F. J. Theis, J. Ring, C. B. Schmidt-Weber, T. Biedermann, S. Eyerich, K. Eyerich, Exp Dermatol 2016, 25, 767.
[46] F. Lauffer, M. Jargosch, L. Krause, N. Garzorz-Stark, R. Franz, S. Roenneberg, A. Böhner, N. S. Mueller, F. J. Theis, C. B. Schmidt-Weber, T. Biedermann, S. Eyerich, K. Eyerich, J Invest Dermatol 2018, 138, 1785.
[47] N. Dand, M. Duckworth, D. Baudry, A. Russell, C. J. Curtis, S. H. Lee, I. Evans, K. J. Mason, A. Alsharqi, G. Becher, A. D. Burden, R. G. Goodwin, K. McKenna, R. Murphy, G. K. Perera, R. Rotarescu, S. Wahie, A. Wright, N. J. Reynolds, R. B. Warren, CEM Griffiths, C. H. Smith, M. A. Simpson, J. N. Barker, M. Benham, S. Hussain, B. Kirby, L. Lawson, K. McElhone, A. Ormerod, C. Owen, M. R. Barnes, P. Di Meglio, R. Emsley, A. Evans, K. Payne, D. Stocken, J Allergy Clin Immunol 2019, 143, 2120.
[48] S. M. Lwin, C. K. Hsu, L. Liu, H. Y. Huang, N. J. Levell, J. A. McGrath, Br J Dermatol 2018, 178, 969.
[49] L. M. Nieto-Benito, O. Baniandrés-Rodríguez, A. Moreno-Torres, A. Hernández-Martín, A. Torrelo-Fernández, M. Campos-Dominguez, J Eur Acad Dermatol Venereol. https://doi.org/10.1111/jdv.16548. Online ahead of print.
[50] S. Wang, Z. Xie, Z. Shen, An Bras Dermatol 2019, 94, 542.
[51] H. Yang, Q. Tan, G. H. Chen, J. S. Chen, Z. Fu, F. L. Ren, X. Y. Luo, H. Wang, J Eur Acad Dermatol Venereol. 2020, 34, 16244.

**How to cite this article:** Neuhauser R, Eyerich K, Boehner A. Generalized pustular psoriasis—Dawn of a new era in targeted immunotherapy. Exp Dermatol. 2020;29:1088–1096. https://doi.org/10.1111/exd.14171